Ophthalmic Opinion Leaders to Shape the Next Generation in
Personalized Medicine with Company’s Genetic Diagnostic and Therapeutic
Technologies
MENLO PARK, Calif.–(BUSINESS WIRE)–Avellino Labs, global biotechnology and genetic science innovators,
announced today that Eric Donnenfeld, M.D., Edward Holland, M.D.,
Richard Lindstrom, M.D. and Elizabeth Yeu, M.D. have joined its board of
medical advisors effective immediately.
“We have long benefitted from the expert input of the world-class
clinicians, many of whom have been a part of the medical advisory team
since Avellino Labs launched in 2008,” said Gene Lee, chairman of the
board for Avellino Labs. “We are profoundly honored to welcome these
respected ophthalmic surgeons to our Medical Advisory Board and look
forward to their insights supporting our strategic market expansion.”
The latest additions to the Avellino Labs medical advisory board include
some of the ophthalmic industry’s most recognizable and respected
physicians and researchers. These U.S.-based opinion leaders have been
instrumental in the development of the most widely implemented
diagnostics and therapeutic treatments for the cornea, including
refractive surgery. Collectively, their demonstrated abilities to
develop science and share it in a meaningful way with the anterior
segment community are the driving factors behind their appointments to
the Avellino Labs medical advisory board.
Each clinician brings a specific focus on innovation and leadership
which will support the development of Avellino Labs’ genetic technology
to deliver more breakthrough products to the clinical practice and shape
the future of personalized medicine in eye care:
Eric Donnenfeld, M.D. is a past president of the American Society
of Cataract and Refractive Surgery and national medical director for TLC
Laser Eye Centers. A clinical professor of ophthalmology at New York
University Medical Center and chief medical editor of EyeWorld, Dr.
Donnenfeld is a well-respected researcher and innovator in ophthalmology
with a specific focus in refractive surgery with an extensive body of
published work. Dr. Donnenfeld is a Fellow of the America Academy of
Ophthalmology and practices at Ophthalmic Consultants of Long Island.
Edward Holland, M.D. is the director of cornea services at
Cincinnati Eye Institute and professor of ophthalmology at the
University of Cincinnati. He is a past president of the American Society
of Cataract and Refractive Surgery, the Cornea Society and the Eye Bank
Association of America. Dr. Holland is a recipient of the prestigious
Binkhorst Medal (2008) and served on the Board of Trustees of the
American Academy of Ophthalmology.
Richard L. Lindstrom, M.D., founder of Minnesota Eye Consultants,
is an internationally-recognized leader in corneal, cataract and
refractive surgery and sought-after keynote and guest lecturer before
professional societies around the world. Known as a pioneer on the
forefront of innovation in ophthalmology, Dr. Lindstrom holds more than
40 patents for pharmaceuticals and medical devices that are used in
clinical practices globally and has made significant contributions to
the science of ophthalmology through his published clinical research.
Elizabeth Yeu, M.D. of Virginia Eye Consultants is an assistant
professor at the Eastern Virginia Medical School. She is editor-in-chief
of U.S. Ophthalmic Review and is the medical editor for Millennial Eye.
Dr. Yeu is a respected expert in refractive cataract surgery, anterior
segment reconstruction and ocular surface disease and serves on several
national medical boards and committees.
With today’s announcement, Avellino’s current medical advisory board now
includes:
Anthony Aldave, M.D.
Andrea Cusumano, M.D.
Burkhard Dick, M.D.
Eric
Donnenfeld, M.D.
Edward Holland, M.D.
David Hwang, M.D.
E.K.
Kim, M.D., PhD
Terry Kim, M.D.
Shigeru Kinoshita, M.D.
Richard
Lindstrom, M.D.
Elizabeth Yeu, M.D.
About Avellino Labs
Avellino Labs is a global leader in gene therapy and molecular
diagnostics and the pioneer in personalized medicine for eye care.
Avellino Labs is pioneering CRISPR gene editing to manage and
potentially cure inherited diseases. Avellino Labs continues to expand
its diagnostics capabilities, building on the success of the world’s
first DNA test to confirm the presence of genetic indicators that are
positively associated with corneal dystrophies, providing life-changing
information for patient treatment decisions and follow-up care. Avellino
Labs is headquartered in Silicon Valley, California, with operations in
Korea, Japan, China and the UK.
Avellino Labs was named a 2015 Technology Pioneer by the World Economic
Forum based on its potential to impact global health.
To learn more, please visit http://www.avellino.com/us/
or follow us on Twitter @Avellinolab_USA.
Contacts
Lisa Spicer, Engaged Communication
(818) 914-2579
lisa@engagedcommunication.net